Atomo Diagnostics Limited (ASX:AT1) is a medical device company headquartered in Sydney, Australia, focused on the global expansion and development of its rapid blood-based test device technologies. Atomo sells its rapid HIV test devices through distribution agreements with international healthcare companies across Europe, Africa, South America, Southeast Asia and Australia.
In response to the global coronavirus pandemic, Atomo has recently begun developing a COVID-19 rapid diagnostic test and plans to commercialise this globally.
Atomo completed its listing on the Australian Securities Exchange raising $30 million in April 2020.
BDO was engaged by Atomo to perform the Independent Accountant and Independent Tax Advisor role for their IPO on the Australian Securities Exchange.
“It gives me great pleasure to share the Board's recognition of all your efforts in helping Atomo prepare for its IPO and life once listed. BDO’s patience and discipline was invaluable to the process, and working with the BDO team was a great experience. We would not hesitate to recommend BDO to anyone seeking an ASX listing.”
John Kelly, Founder & Managing Director,
Atomo Diagnostics Limited